Portfolio Companies News
April 16, 2018Aprea Therapeutics Presents Results...
- ORR (by IWG) of 100% in all evaluable patients: 6 CR (75%) and 2 mCR (25%) - All CR patients achieved complete cytogenetic response - No responding patients have experienced relapse - No treatment-related serious adverse events or dose-limiting toxicities to date BOSTON, MA. and STOCKHOLM, S... read more
April 16, 2018Nordic Nanovector Presents Preclini...
Oslo, Norway, 16 April 2018 Nordic Nanovector ASA (OSE: NANO) announces that a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma (NHL) was presented yesterday at the Amer... read more
April 12, 2018Targovax strengthens Board of Direc...
Thursday, April 12, 2018 Oslo, Norway, 12 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the appointment of Catherine Wheeler MD to the Targovax Board of Directors Catherine has had a lo... read more
April 12, 2018First patient starts treatment in O...
April 12, 2018 Press releases Stockholm – 12 April 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company’s Phase I / II ANCHOR trial designed to study Ygalo® in multiple myeloma patients in combination with ... read more
April 12, 2018Promising preliminary long-term dat...
Apr 12, 2018 Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under invest... read more
February 07, 2018Q4 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.